8-K: GoodRx Appoints Scott Wagner to Board of Directors and Co-Chair Role

GoodRx Holdings, Inc. has appointed Scott Wagner to its Board of Directors, as Co-Chair, and Chair of the Compensation Committee, following the resignation of Simon Patterson.

Summary

• GoodRx Holdings, Inc. appointed Scott Wagner to its Board of Directors as a Class II director on January 21, 2025.
• Mr. Wagner will also serve as Co-Chair of the Board alongside Trevor Bezdek and as Chair of the Compensation Committee.
• He previously served as the company's Interim CEO from April 2023 to January 2025.
• Mr. Wagner brings over 25 years of executive leadership experience, including his time at GoDaddy where he oversaw significant revenue growth.
• Simon Patterson resigned from the Board and its Nominating and Corporate Governance and Innovation Committees on the same day.
• The vacancy created by Mr. Patterson's resignation was filled by Mr. Wagner's appointment, which was recommended by the Nominating and Corporate Governance Committee.
• Mr. Wagner will receive standard compensation for non-employee directors, including an initial RSU award valued at $420,000 and a pro-rated annual RSU award valued at $85,699.
• He will also receive an annual cash retainer of $30,000 for his board service and an additional $15,000 for chairing the Compensation Committee, both pro-rated for 2025.
• Mr. Wagner is eligible for an annual RSU award valued at $230,000 if serving on the board at the time of the annual meeting.
• He can defer his cash retainers and RSU settlements under the company's Deferred Compensation Plan for Directors.

Sentiment

Score: 7

Explanation: The document is generally positive due to the appointment of an experienced executive to the board, but it also includes the resignation of a board member, which introduces a slight element of uncertainty. The overall tone is professional and neutral.

Positives

• Scott Wagner's appointment brings significant executive leadership experience to the Board, including his successful tenure at GoDaddy.
• His previous role as Interim CEO provides him with a deep understanding of GoodRx's operations.
• The appointment of a Co-Chair may enhance the Board's leadership structure.
• The compensation package for Mr. Wagner is in line with the company's standard non-employee director compensation program.

Negatives

• The resignation of Simon Patterson creates a vacancy on the Board and its committees, although this was filled by Mr. Wagner.
• The document does not provide any specific reason for Mr. Patterson's resignation.

Risks

• The transition of board members could introduce some uncertainty, although the appointment of Mr. Wagner is intended to mitigate this.
• The company's reliance on key personnel means that any future changes in leadership could pose a risk.

Future Outlook

The document does not contain any specific forward-looking statements or guidance beyond the details of Mr. Wagner's appointment and compensation.

Management Comments

• The Board believes Mr. Wagner is qualified to serve as a director due to his experience serving as Interim Chief Executive Officer of the Company, as well as his experience serving as a director and officer for high-growth tech companies.
• Mr. Pattersons decision to resign is not the result of any disagreement with the Company or its management on any matter relating to the Companys operations, policies or practices.

Industry Context

The appointment of a seasoned executive like Scott Wagner, with experience at high-growth tech companies, suggests GoodRx is focusing on strategic growth and operational efficiency. This is a common trend in the tech industry where companies seek experienced leaders to navigate competitive landscapes.

Comparison to Industry Standards

• The compensation package for Mr. Wagner, including cash retainers and RSU awards, is consistent with standard practices for non-employee directors at publicly traded technology companies.
• The appointment of a former CEO to the board is a common practice to leverage their experience and insights.
• The use of a Stockholders Agreement to fill board vacancies is a standard mechanism for companies with significant institutional investors, similar to companies like Lyft and Uber.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Scott Wagner positively, given his experience and previous role as Interim CEO.
• Employees may experience a change in leadership dynamics with the new board appointments.
• The changes are unlikely to have a direct impact on customers, suppliers, or creditors.

Next Steps

• Mr. Wagner will begin his service as a Class II director, Co-Chair of the Board, and Chair of the Compensation Committee.
• The company will proceed with the vesting schedule for Mr. Wagner's RSU awards.
• The company will continue to operate under the terms of the Stockholders Agreement.

Key Dates

Keywords

Board of Directors, Scott Wagner, Corporate Governance, Compensation Committee, Executive Leadership, Director Appointment, Resignation, GoodRx, RSU, Non-Employee Director